Stevanato Group has beaten earnings estimates in 3 of the last 4 quarters with consistent 5-10% upside surprises and analyst targets implying 28% price upside, but the stock is in a confirmed downtrend with a death cross and free cash flow that is negative 40% relative to net income, creating a gap between earnings quality and analyst optimism.
Thesis pillars
- Earnings Beat Analyst Upside→Stable
- Death Cross Confirmed Downtrend→Stable
- Fcf Earnings Quality Divergence→Stable
- +1 more pillar — see the Why tab for full reasoning
Stevanato Group S.p.A. (STVN) Stock Analysis
Recovery setup
Healthcare · Medical Instruments & Supplies
Sell if holding. At $19.00, A.R:R 0.8:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak overall score: 4.7/10; Weak growth.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two... Read more
Sell if holding. At $19.00, A.R:R 0.8:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak overall score: 4.7/10; Weak growth. Chart setup: Death cross but MACD improving, RSI 63. Score 4.7/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 30d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-07-06Recent Developments — Stevanato Group S.p.A.
Latest news
- NEWS Stevanato Group (NYSE:STVN) Sees Unusually-High Trading Volume - Should You Buy? - MarketBeat — MarketBeat neutral
- NEWS Stevanato S p A : Report on Remuneration Policy and Practices 2026 - marketscreener.com — marketscreener.com neutral
- NEWS Stevanato S p A : Report of the Audit Committee to the Shareholders on the Activities Carried Out in the Financial Year — marketscreener.com neutral
- NEWS Stevanato Group (STVN) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance — Yahoo Finance positive
- NEWS Stevanato Group Files Form 6-K Detailing Q1 2026 Results Presentation - TipRanks — TipRanks neutral
Generated 2026-07-06T11:41:43Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $19.00, A.R:R 0.8:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak overall score: 4.7/10; Weak growth. Chart setup: Death cross but MACD improving, RSI 63. Prior stop was $17.67. Score 4.7/10, moderate confidence.
Take-profit target: $21.27 (+11.9% upside). Prior stop was $17.67. Stop-loss: $17.67.
Weak overall score: 4.7/10; Weak growth; Below 200-MA, MA slope -4.2%/30d (confirmed downtrend).
Stevanato Group S.p.A. trades at a P/E of 32.8 (forward 22.7). TrendMatrix value score: 4.1/10. Verdict: Sell.
17 analysts cover STVN with a consensus score of 4.2/5. Average price target: $24.
What does Stevanato Group S.p.A. do?Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide...
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.